Skip to main content

Quick Connect

CPHI Milan 2024

Connect with our API experts and explore industry-leading solutions.

Meet us at booth 24A41

October 08 - 10, 2024
Fiera Milano, Italy
Schedule a meeting
Verified

Our Team at CPHI Milan 2024

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API  business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

  • 250+ APIs

  • 8 Manufacturing sites

  • More than 1873 drug master files across global markets.

  • Over 325 ANDAs

  • More than 1000 patents field, and more than 70 own patents granted

  • Experience with complex APIs and formulations supporting early market entries.

  • Preferred pharma API supplier for pharma companies in more than 80 countries.

Sustainability is deeply embedded in our purpose and forms the core of our organization.

Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability.

By the end of FY2024, we had served over 700 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.

What we achieved in the past year:

 

Our Plants

About CPHI Milan 2024

CPHI Milan is a global pharmaceutical event uniting the pharmaceutical community to advance human health. With a history spanning 35 years, the event has become a cornerstone for fostering connections and inspiring partnerships across the industry. CPHI Milan is a platform for professionals to engage with the latest innovations, share knowledge, and collaborate on projects that shape the future of pharmaceuticals.

Key Highlights of CPHI Milan 2024:

  • Global Participation: The event expects to welcome 62,000 attendees and 2,400 exhibitors from 168+ countries, demonstrating its significant international reach.

  • Diverse Exhibition: Attendees can explore a wide range of products and services across various pharmaceutical sectors.

  • Networking Opportunities: CPHI Milan offers numerous opportunities for attendees to connect, build relationships, and forge partnerships.

  • Knowledge Exchange: The event features conferences, seminars, and workshops where industry experts share insights and discuss the latest trends.

  • Celebration of 35 Years: CPHI Milan 2024 marks a special milestone, celebrating 35 years of uniting the pharma community.

Our Achievement (awards)

Company

Follow Us on

© 2024 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.